KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Common Equity (2017 - 2026)

Twist Bioscience has reported Common Equity over the past 10 years, most recently at $455.1 million for Q1 2026.

  • Quarterly Common Equity rose 3.41% to $455.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $455.1 million through Mar 2026, up 3.41% year-over-year, with the annual reading at $473.0 million for FY2025, 0.06% changed from the prior year.
  • Common Equity was $455.1 million for Q1 2026 at Twist Bioscience, roughly flat from $456.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $863.4 million in Q1 2022 and troughed at $440.1 million in Q1 2025.
  • The 5-year median for Common Equity is $560.1 million (2024), against an average of $592.8 million.
  • Year-over-year, Common Equity soared 40.57% in 2022 and then fell 25.31% in 2024.
  • A 5-year view of Common Equity shows it stood at $746.3 million in 2022, then fell by 20.94% to $590.0 million in 2023, then decreased by 22.73% to $455.9 million in 2024, then increased by 0.03% to $456.1 million in 2025, then fell by 0.22% to $455.1 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Common Equity are $455.1 million (Q1 2026), $456.1 million (Q4 2025), and $473.0 million (Q3 2025).